TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Matthew J Maurer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.